Journal
JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 103, Issue 3, Pages 777-784Publisher
ELSEVIER SCIENCE INC
DOI: 10.1002/jps.23879
Keywords
nanotechnology; materials science; drug delivery systems; regulatory science; EMA; US FDA; toxicity; nanoparticles; regulations; government
Ask authors/readers for more resources
Nanomaterials have become part of formulation development in the pharmaceutical industry and offer exciting opportunities in the area of targeted drug delivery. But they may also exert unexpected toxicities and potentially pose a threat to human health and the environment. Since the Scientific Committee on Emerging and Newly Identified Health Risks recommended a definition of nanomaterials for implementation into the existing and upcoming regulatory framework in the European Union, a discussion about safety requirements of new nanoscale products has emerged. At the same time, the Food and Drug Administration of the United States still observes recent developments in this area. Although the impact on the pharmaceutical product chain is still uncertain, guidelines on risk assessment in food products and cosmetics are available and offer a preview of future developments in the regimens of pharmaceuticals. (c) 2014 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available